Search Results

Viking Therapeutics, Inc. today announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association.

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Sciwind Biosciences Co., Ltd. announced that the company will present positive results from a Phase 3 clinical study of injectable ecnoglutide in T2DM patients and from a Phase 1 study for oral ecnoglutide in healthy and healthy obese participants, as well as preclinical data for novel amylin analog programs, at the American Diabetes Association 84th Annual Conference.

Zealand Pharma A/S announced presentations of clinical and non-clinical results for Zealand’s amylin analog ZP8396 at the Obesity Society Annual Meeting being held in Dallas, Texas from October 14-17, 2023.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Zealand Pharma A/S announced results from Part 1 of a multiple ascending dose trial for ZP8396, the company’s long-acting amylin analog with potential for the management of overweight and obesity.

Nika Pharmaceuticals, Inc. introduces its plans to develop the company into a sustainable business project that will consistently grow, bring good profits and provide dividends to its shareholders.

Bexion Pharmaceuticals, Inc. announced that the Company will present at the 2024 Biotechnology Innovation Organization International Convention taking place June 3-6, 2024, in San Diego, California.

Future Pak, LLC and its affiliates announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. in a good faith effort to acquire all outstanding shares of Vanda.